Family with sequence similarity 76 member B (FAM76B)

Family with sequence similarity 76 member B (FAM76B) is a protein-coding gene whose product is a nuclear speckle-localized protein of approximately 39 kDa, consisting of 339 amino acids and containing homopolymeric histidine tracts[1][2][3]. FAM76B acts as a negative regulator of inflammation, particularly by inhibiting the NF-κB-mediated inflammatory pathway[1][5]. It achieves this by preventing the translocation of hnRNPA2B1 from the nucleus to the cytoplasm, thereby inhibiting the downstream activation of pro-inflammatory genes such as IL-6[1][5]. This protein is expressed in diverse tissues including the brain, lymph nodes, and spleen, and is highly expressed in immune cell types such as macrophages[1][7]. In experimental models, knockout or knockdown of FAM76B leads to a marked increase in inflammatory cytokine production and macrophage activation, especially in response to TBI and other inflammatory insults[1]. FAM76B is not a classical therapeutic target such as an enzyme, receptor, or transporter. To date, there are no reported drugs that directly target FAM76B, nor is it established as a biomarker for patient selection or monitoring. However, its role in neuroinflammation, neurodegenerative disease, and systemic inflammatory pathways make it of emerging research interest, particularly in diseases where NF-κB signaling is implicated[1][3]. Some rare Mendelian diseases (Type 1 diabetes mellitus 17, Carboxypeptidase N deficiency) have been genetically associated with variants in FAM76B[3]. There are no major safety concerns or therapeutic challenges described for FAM76B, but its biological modulation could theoretically impact inflammatory homeostasis. FAM76B is currently best described as a regulator of nuclear-cytoplasmic trafficking for proteins involved in mRNA processing and inflammation, with specific relevance to NF-κB pathway control in innate immune responses and neuroinflammation[1][3][5].

Other names

Protein FAM76BMGC33371